Harm Reduction Box
Mechanism Exchange & Repair Aids in Fighting Opioid Overdoses Through Narcan Distribution Sites
December 08, 2022 09:00 ET | Mechanism Exchange & Repair, Inc.
YOAKUM, Texas, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Mechanism Exchange & Repair, Inc. (MER), one of the last manufacturers of Newspaper Vending Machines, is finding their distribution boxes make...
Stop Opioid Overdoes Naloxone
Fentanyl Drives Fatal Overdoses to Over 107,000 Annually in the U.S. - Healthcare Providers' Effort to Fight Back
August 24, 2022 09:00 ET | Cordant Health Solutions
PORTLAND, Ore., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Cordant Health Solutions®, a leader in providing innovative tools for addiction treatment programs, is partnering with addiction treatment providers...
22157.jpg
Naloxone Spray Global Market is Expected to Reach $785.35 Million in 2025 at a CAGR of 22.3%
December 29, 2021 05:58 ET | Research and Markets
Dublin, Dec. 29, 2021 (GLOBE NEWSWIRE) -- The "Naloxone Spray Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering. The global...
22157.jpg
Global $3.35 Bn Naloxone (Parenteral, Intranasal, & Sublingual) Markets, 2019-2020 & Forecast to 2027
May 13, 2021 04:43 ET | Research and Markets
Dublin, May 13, 2021 (GLOBE NEWSWIRE) -- The "Naloxone Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2021 to...
emergent logo.jpg
UPDATE -- Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 11:54 ET | Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
emergent logo.jpg
Emergent BioSolutions Announces FDA Approval of NARCAN® (naloxone HCl) Nasal Spray Shelf Life Extension to 36 Months
August 17, 2020 06:30 ET | Emergent BioSolutions
GAITHERSBURG, Md., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved the extension of the shelf...
emergent logo.jpg
Emergent BioSolutions Statement on U.S. District Court Decision
June 05, 2020 19:39 ET | Emergent BioSolutions
GAITHERSBURG, Md., June 05, 2020 (GLOBE NEWSWIRE) -- Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal...
emergent logo.jpg
Emergent BioSolutions to Offer All Public Libraries and YMCAs in the U.S. Free Opioid Awareness Education and NARCAN® (naloxone HCl) Nasal Spray
October 24, 2018 14:30 ET | Emergent BioSolutions
New initiatives make free doses and educational materials available to thousands of public libraries & YMCAs in the U.S. GAITHERSBURG, Md., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Emergent...
Aegis Expands its In
Aegis Expands its International and US Intravail® Patent Portfolio on Multiple Fronts
August 02, 2018 06:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded European Patent No. EP2381773(B1) and Canadian Patent No. 2,748,268, providing fast...
Aegis Awarded Patent
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
February 22, 2018 08:00 ET | Aegis Therapeutics LLC
SAN DIEGO, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,895,444 providing non-invasive metered nasal spray delivery of multiple...